Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
AstraZeneca’s trial lives up to its billing, though the benefit might be subgroup-driven, and comes at the cost of toxicity.
Adding a kinase inhibitor to PD-L1 plus chemo could make a real difference in first-line SCLC, a little-appreciated Chinese trial suggests.
One first-in-human study and two deals in a single day sees companies blaze the ADC trail.
CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.
Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.